Gsk Plc · LSE:GSK
Gsk — ViiV Healthcare — Investor Day (September 2023)
31 slides from Gsk's investor day presentation, Sep 28, 2023
Slide 1: ViiV Healthcare Meet the Management: Getting Ahead of HIV Together
ViiV Healthcare Meet the Management Getting Ahead of HIV Together 28 September 2023 1
Slide 2: Cautionary statement regarding forward-looking statements
Cautionary statement regarding forward-looking statements This presentation relates to ViiV Healthcare and all guidance, projections and forecasts pertain to ViiV Healthcare rather than the GSK group as a whole. This presentation may contain forward-looking statements. Forward-looking statements giv
Slide 3: Agenda
Agenda 100% focused Reshaping the HIV Leaders and on HIV – innovation treatment disruptors in leaders for 35 years and prevention innovation – the market future is long-acting Q&A David Redfern Deborah Waterhouse Kimberly Smith, MD, MPH President, Corporate Development, CEO, ViiV Healthcare Head of
Slide 4: Leaders in HIV focused on ending the global epidemic
Leaders in HIV focused on ending the global epidemic Our mission is to leave no Leaders and Focused and agile, Built on novel Strong commitment person living with HIV disruptors backed by collaborations and to communities behind. in innovation scale of GSK powerful partnerships 2009 2012 2013 2016 2
Slide 5: Reshaping the HIV treatment and prevention market
Reshaping the HIV treatment and prevention market Deborah Waterhouse CEO, ViiV Healthcare and President Global Health, GSK 5
Slide 6: 6
6
Slide 7: Recap of our 2021 commitments
Recap of our 2021 commitments • Pioneering innovation for treatment and prevention • Mid-single digit sales CAGR 2021-26 • Dovato and cabotegravir drive growth via competitive execution • Cabotegravir long-acting (LA) portfolio replaces dolutegravir (DTG) as foundational medicine • Innovative LA pip
Slide 8: What’s new today
What’s new today 1. 2021-2026 sales CAGR upgraded to 6% - 8%* 2. Dosing intervals for long-acting regimens increased to every-four-months in prevention and treatment 3. Roadmap to extend dosing interval to every-six-months by end of decade 4. IP for Dovato and Juluca is anticipated to extend through
Slide 9: Strong commercial execution driving growth
Strong commercial execution driving growth 9
Slide 10: Strong execution drives 2021-2026 CAGR upgrade to 6% - 8%
Strong execution drives 2021-2026 CAGR upgrade from mid-single digits to 6% - 8%* ~£7bn sales in 2026 2026-31 2021-26 LA pipeline growth drivers growth drivers Ultra-long-acting (ULA) for Dovato PrEP Cabenuva Oral two-drug regimens ULA for treatment Other oral portfolio LA portfolio Self-administere
Slide 11: Fastest growing company in HIV in both sales and market share
Fastest growing company in HIV in both sales and market share • Fastest growing company in HIV “I want a treatment that will keep me driven by strong innovation and undetectable with fewer medicines” Leading oral 2-drug regimen execution • Dovato sales on track to deliver £2bn in 2024 • LA portfolio
Slide 12: Growth of long-acting portfolio and extended exclusivity reduces impact of DTG LOE
Growth of long-acting portfolio and extended period of exclusivity reduces impact of DTG LOE • ~40% of ViiV revenue estimated 2027 DBR* to be in long-acting by 2027 2027 sales breakdown Loss of exclusivity timing breakdown • DTG composition of matter protection until April 2028 in US and July 2029 i
Slide 13: Reshaping the HIV market to long-acting
Reshaping the HIV market to long-acting 13
Slide 14: Key trends shaping HIV treatment and prevention
Key trends shaping HIV treatment and prevention Continued HIV transmission Stigma and inequity persist 1.5m new cases of HIV per With key populations and year1 marginalised groups disproportionally affected LA, oral and injectable, Community engagement high dominate pipelines based Strong focus on a
Slide 15: ViiV Healthcare’s leadership in LA drives market dynamism
ViiV Healthcare’s leadership in LA drives market dynamism in treatment and prevention Global HIV treatment market value Global PrEP market value 100% 100% 80% 80% 60% 60% 40% 40% 20% 20% 0% 0% 2022 2031 2022 2031 LA Inj. Orals LA inj. Orals • LA injectables expected to represent ~30% of the treatmen
Slide 16: An industry-leading pipeline driven by patient insights
An industry-leading pipeline driven by patient insights Kimberly Smith, MD, MPH Head of R&D, ViiV Healthcare 16
Slide 17: Industry-leading pipeline delivering the next wave of innovation
Industry-leading pipeline delivering the next wave of innovation Search for remission and cure Target product profiles 1. Ultra-long-acting (ULA) PrEP 2. ULA treatment 3. Self-administered treatment Long-acting prevention Apretude (cabotegravir) Pipeline assets1,3 • Reformulated cabotegravir Attachm
Slide 18: Insight driven, long-acting patient profiles across treatment and prevention
Insight driven, long-acting patient profiles across treatment and prevention ULA prevention ULA treatment Self-administered LA treatment “It’s definitely going to “If I can go for several “I like the save me time. I won’t months without convenience. You’re need to pick up burden, without not tied do
Slide 19: Integrase inhibitors (INSTI) at the core of HIV treatment and prevention
Integrase inhibitors (INSTI) at the core of HIV treatment and prevention ViiV Healthcare continues to lead in INSTI innovation 76% share for integrase inhibitors across • INSTIs are the foundation of ART regimens in top 9 markets* HIV treatment guidelines around the world1,2 80% • Gold standard stat
Slide 20: Cabotegravir LA is transformative
Cabotegravir LA is transformative “I think what people are saying is, when is it going to be every three months…when is it going to be every six months? And that’s pretty exciting because they’re really enjoying the long-acting therapy.” Dr. Gary Blick, Co-founder HIV Advocates 20
Slide 21: Cabotegravir LA: robust data drives momentum and success
Cabotegravir LA: robust data drives momentum and success Switching to cabotegravir and rilpivirine LA every-two-months was Study revealed that among participants who chose cabotegravir, 77% cited associated with improved treatment satisfaction, preferred by 90% of preferring injections as the reason
Slide 22: Doubling the dosing interval of cabotegravir to every-four-months
Doubling the dosing interval of cabotegravir to every-four-months in treatment and PrEP New formulation of cabotegravir In PrEP, for launch in 2026: • CAB 400 • Double the concentration of the current cabotegravir (CAB) formulation In treatment, two potential partners for launch in 2027: • >2x half-
Slide 23: Option one: evolving Cabenuva with CAB 400 + RPV
Option one: evolving Cabenuva with CAB 400 + RPV q Improved patient Builds on HCP and experience with fewer patient confidence clinic visits and familiarity Working with Janssen to evaluate alternative RPV half-life of ~200 Potential to improve doses and formulations days1 the patient and clinic exp
Slide 24: Option two: CAB 400 + VH109 (N6LS) advances to phase IIb
Option two: CAB 400 + VH109 (N6LS) advances to phase IIb clinical trial VH109 is a novel bNAb with Single dose in humans broad and potent neutralisation demonstrated viral load activity reductions up to -2.8 log/ml1-3 in vitro 1 • Neutralises up to 98% of viral strains1 d VH109 + rHuPH20 delivers Ph
Slide 25: Next generation LA regimens with INSTIs at the core
Next generation LA regimens with INSTIs at the core Novel methods of action offer multiple options for development of new LA regimens 1 2 3 4 5 Binding and Nuclear entry Integration Assembly and Maturation fusion and uncoating budding Class: bnAb Class: Capsid Class: INSTI Class: INSTI Class: INSTI
Slide 26: Multiple pathways to deliver long-acting treatment and prevention
Multiple pathways to deliver long-acting treatment and prevention Asset Self-administered ULA Q4M ULA Q6M CAB 400 (INSTI) VH184 (INSTI) VH310 (INSTI) VH109 (bNAb N6LS) VH937 (maturation inhibitor) VH280/VH499 (capsid inhibitor) NRTTI (rilpivirine) 26
Slide 27: Clear roadmap of innovation delivery
Clear roadmap of innovation delivery INSTI-based LA regimens anchor pipeline TPPs Key milestones 2023 2024 2025 2026 2027 2028 - 2030 Q4M Q4M file and Q6M registrational Q6M file and ULA PrEP registrational launch study start launch study start (H1) CAB 400 dose Q4M file and launch selection Q4M Q6M
Slide 28: LA is the key to ending the HIV epidemic
LA is the key to ending the HIV epidemic ViiV Healthcare continues to lead the way 28
Slide 29: Reshaping the HIV treatment and prevention market
Reshaping the HIV treatment and prevention market Deborah Waterhouse CEO, ViiV Healthcare and President Global Health, GSK 29
Slide 30: Our updated commitments
Our updated commitments • Pioneering innovation for treatment and prevention • 6% to 8% sales CAGR 2021-26 • Dovato and cabotegravir drive growth via competitive execution • Cabotegravir LA portfolio replaces dolutegravir as foundational medicine • LA performance and pipeline offers the potential to
Slide 31: Q&A
Q&A 31